Chemify, a Glasgow, Scotland, UK-based developer of chemputation technology that allows the digital design, discovery & manufacture of complex molecules and materials, raised $43m in Series A funding.
The round was led by Triatomic Capital, joined by new investors including Horizon Ventures, Rocketship Ventures, Possible Ventures, Alix Ventures, Eos, and the UK Government Innovation Accelerators program, as well as existing investor BlueYard Capital.
Founded in 2019 by CEO Lee Cronin with backing from David Cleevely (co-founder of Abcam), Chemify leverages decades of chemistry research, robotics, AI, and conceptual advancements from Cronin’s Digital Chemistry Laboratory at the University of Glasgow in Scotland to help reduce the amount of experimentation required to discover new molecules, speeding up their development as products to underpin advances in medicine, farming, materials science, and green energy.
The underlying proprietary molecular design, discovery, and chemical manufacturing technology was designed and developed by Cronin and his team at the University of Glasgow, based at the Mazumdar-Shaw Advanced Research Centre.
FinSMEs
02/08/2023